Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: A prospective study

Journal of Interventional Cardiology

Volumn 21, Issue 5, 2008, Pages 388-394

  Toutouzas, Konstantinos ^a,b   Patsa, Chrysoula ^a   Tsiamis, Eleftherios ^a   Tsioufis, Costas ^a   Spanos, Anastasios ^a   Stefanadi, Elli ^a   Tentolouris, Costas ^a   Stefanadis, Christodoulos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; ZOTAROLIMUS;

ADULT; AGED; ARTICLE; BARE METAL STENT; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG WITHDRAWAL; EXERCISE TEST; FATALITY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IN STENT RESTENOSIS; INCIDENCE; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MALE; METAL IMPLANTATION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; REVASCULARIZATION; STENT; THROMBOSIS; TREATMENT OUTCOME;

AGED; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; EXERCISE TEST; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIA; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 52649110559     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2008.00381.x     Document Type: Article

References (57)

1. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: Current status and future strategies. J Am Coll Cardiol 2002 39:183 193.
2. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004 350:221 231.
3. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002 346:1773 1780.
4. Toutouzas K, Di Mario C, Falotico R, et al. Sirolimus-eluting stents: A review of experimental and clinical findings. Z Kardiol 2002 91 (Suppl 3):49 57.
5. Papafaklis MI, Michalis LK. Long-term outcome after coronary angioplasty: Where do we stand? Hellenic J Cardiol 2005 46:375 379.
6. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999 100:1872 1878.
7. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001 344:250 256.
8. Waksman R, Raizner AE, Yeung AC, et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: The INHIBIT randomised controlled trial. Lancet 2002 359:551 557.
9. di Mario C. TK. No room for radiant dreams in the real world. Eur Heart J 2002 23:999 1001.
10. Stone GW, Ellis SG, O'Shaughnessy CD, et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA 2006 295:1253 1263.
11. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2003 107:24 27.
12. Tanabe K, Serruys PW, Grube E, et al. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003 107:559 564.
13. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: The first clinical experience. J Am Coll Cardiol 2003 41:184 189.
14. Commeau P, Barragan PT, Roquebert PO, et al. ISR II Study: A long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions. Catheter Cardiovasc Interv 2005 66:158 162.
15. Schiele TM, Konig A, Rieber J, et al. Sirolimus-eluting stent implantation and beta-irradiation for the treatment of in-stent restenotic lesions: Comparison of underlying mechanisms of acute gain and late loss as assessed by volumetric intravascular ultrasound. Am Heart J 2005 150:351 357.
16. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005 293:165 171.
17. Beijk MA, Piek JJ. XIENCE V everolimus-eluting coronary stent system: A novel second generation drug-eluting stent. Expert Rev Med Devices 2007 4:11 21.
18. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004 109:2168 2171.
19. Serruys PW, Ong AL, Piek J. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Eurointervention 2005 1:58 65.
20. Serruys PW, Ruygrok, Neuzner, J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Eurointervention 2006 2:286 294.
21. Beijk MA, Neumann F, Wiemer M. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). Eurointervention 2007 3:206 212.
22. Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent. Catheter Cardiovasc Interv 2006 68:97 103.
23. Tsuchida K, Piek JJ, Neumann F. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT First Trial). Eurointervention 2005 1:266 272.
24. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006 114:798 806.
25. Gershlick A, Kandzari DE, Leon MB, et al. Zotarolimus-eluting stents in patients with native coronary artery disease: Clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007 100:45M 55M.
26. Meredith IT, Ormiston J, Whitbourn R, et al. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 2007 100:56M 61M.
27. Jain AK, Meredith IT, Lotan C, et al. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: Early data from the E-Five Registry. Am J Cardiol 2007 100:77M 83M.
28. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent. J Interv Cardiol 2006 19:405 413.
29. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007 115:2344 2351.
30. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997 336:1697 1703.
31. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000 101:2165 2171.
32. Waksman R, Bhargava B, White L, et al. Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 2000 101:1895 1898.
33. Holmes DR Jr., Teirstein P, Satler L, et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The SISR randomized trial. JAMA 2006 295:1264 1273.
34. Airoldi F, Rogacka R, Briguori C, et al. Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. Am J Cardiol 2004 94:1297 1300.
35. Kim YH, Lee BK, Park DW, et al. Comparison with conventional therapies of repeated sirolimus-eluting stent implantation for the treatment of drug-eluting coronary stent restenosis. Am J Cardiol 2006 98:1451 1454.
36. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005 353:663 670.
37. Worthley MI, Anderson TJ, Traboulsi M, et al. Registry data evaluating the effectiveness of drug-eluting stents for the treatment of symptomatic in-stent restenosis. Heart Lung Circ 2006 15:300 305.
38. Belardi JA, Cura F, Albertal M, et al. Use of drug-eluting stents for the treatment of in-stent restenosis in routine clinical practice. Coron Artery Dis 2005 16:327 330.
39. Vaina S, Ong AT, Serruys PW. New drug-eluting stents, optimizing technique, and the problem of drug-eluting stent restenosis. Minerva Cardioangiol 2005 53:341 360.
40. Saia F, Lemos PA, Arampatzis CA, et al. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: Insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 2004 90:1183 1188.
41. Saia F, Lemos PA, Hoye A, et al. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 2004 62:283 288.
42. Airoldi F, Briguori C, Iakovou I, et al. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J Cardiol 2006 97:1182 1187.
43. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. Minerva Cardioangiol 2007 55:1 18.
44. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: A randomized controlled trial. J Am Coll Cardiol 2006 48:2440 2447.
45. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007 356:998 1008.
46. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007 356:989 997.
47. Nakazawa G, Finn AV, Virmani R. Vascular pathology of drug-eluting stents. Herz 2007 32:274 280.
48. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007 356:1020 1029.
49. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007 356:1009 1019.
50. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007 356:1030 1039.
51. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004 109:1930 1932.
52. Kuchulakanti PK, Chu WW, Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 2006 113:1108 1113.
53. Park DW, Park SW, Park KH, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006 98:352 356.
54. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005 45:954 959.
55. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006 48:193 202.
56. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007 115:2435 2441.
57. Nakazawa G, Finn AV, John MC, et al. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007 100:36M 44M.